Japan
· Delayed Price · Currency is JPY Astellas Pharma Statistics
Total Valuation
Astellas Pharma has a market cap or net worth of JPY 4.13 trillion. The enterprise value is 4.42 trillion.
| Market Cap | 4.13T |
| Enterprise Value | 4.42T |
Important Dates
The last earnings date was Monday, April 27, 2026.
| Earnings Date | Apr 27, 2026 |
| Ex-Dividend Date | Mar 30, 2026 |
Share Statistics
Astellas Pharma has 1.79 billion shares outstanding. The number of shares has decreased by -0.00% in one year.
| Current Share Class | 1.79B |
| Shares Outstanding | 1.79B |
| Shares Change (YoY) | -0.00% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.02% |
| Owned by Institutions (%) | 53.70% |
| Float | 1.79B |
Valuation Ratios
The trailing PE ratio is 14.22 and the forward PE ratio is 12.55. Astellas Pharma's PEG ratio is 0.19.
| PE Ratio | 14.22 |
| Forward PE | 12.55 |
| PS Ratio | 1.93 |
| PB Ratio | 2.26 |
| P/TBV Ratio | 10.57 |
| P/FCF Ratio | 8.22 |
| P/OCF Ratio | 7.37 |
| PEG Ratio | 0.19 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.71, with an EV/FCF ratio of 8.79.
| EV / Earnings | 15.15 |
| EV / Sales | 2.06 |
| EV / EBITDA | 7.71 |
| EV / EBIT | 11.68 |
| EV / FCF | 8.79 |
Financial Position
The company has a current ratio of 1.17, with a Debt / Equity ratio of 0.31.
| Current Ratio | 1.17 |
| Quick Ratio | 0.86 |
| Debt / Equity | 0.31 |
| Debt / EBITDA | 0.98 |
| Debt / FCF | 1.13 |
| Interest Coverage | 27.01 |
Financial Efficiency
Return on equity (ROE) is 17.44% and return on invested capital (ROIC) is 13.91%.
| Return on Equity (ROE) | 17.44% |
| Return on Assets (ROA) | 6.88% |
| Return on Invested Capital (ROIC) | 13.91% |
| Return on Capital Employed (ROCE) | 16.18% |
| Weighted Average Cost of Capital (WACC) | 4.68% |
| Revenue Per Employee | 156.80M |
| Profits Per Employee | 21.37M |
| Employee Count | 13,643 |
| Asset Turnover | 0.62 |
| Inventory Turnover | 1.30 |
Taxes
In the past 12 months, Astellas Pharma has paid 85.01 billion in taxes.
| Income Tax | 85.01B |
| Effective Tax Rate | 22.57% |
Stock Price Statistics
The stock price has increased by +66.92% in the last 52 weeks. The beta is 0.15, so Astellas Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.15 |
| 52-Week Price Change | +66.92% |
| 50-Day Moving Average | 2,493.52 |
| 200-Day Moving Average | 1,989.18 |
| Relative Strength Index (RSI) | 32.24 |
| Average Volume (20 Days) | 4,925,510 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Astellas Pharma had revenue of JPY 2.14 trillion and earned 291.54 billion in profits. Earnings per share was 162.22.
| Revenue | 2.14T |
| Gross Profit | 1.73T |
| Operating Income | 380.06B |
| Pretax Income | 376.59B |
| Net Income | 291.54B |
| EBITDA | 574.65B |
| EBIT | 380.06B |
| Earnings Per Share (EPS) | 162.22 |
Balance Sheet
The company has 281.61 billion in cash and 565.95 billion in debt, giving a net cash position of -284.35 billion or -158.72 per share.
| Cash & Cash Equivalents | 281.61B |
| Total Debt | 565.95B |
| Net Cash | -284.35B |
| Net Cash Per Share | -158.72 |
| Equity (Book Value) | 1.83T |
| Book Value Per Share | 1,020.96 |
| Working Capital | 203.52B |
Cash Flow
In the last 12 months, operating cash flow was 560.19 billion and capital expenditures -57.72 billion, giving a free cash flow of 502.47 billion.
| Operating Cash Flow | 560.19B |
| Capital Expenditures | -57.72B |
| Depreciation & Amortization | 194.59B |
| Net Borrowing | -282.89B |
| Free Cash Flow | 502.47B |
| FCF Per Share | 280.47 |
Margins
Gross margin is 80.91%, with operating and profit margins of 17.77% and 13.63%.
| Gross Margin | 80.91% |
| Operating Margin | 17.77% |
| Pretax Margin | 17.60% |
| Profit Margin | 13.63% |
| EBITDA Margin | 26.86% |
| EBIT Margin | 17.77% |
| FCF Margin | 23.49% |
Dividends & Yields
This stock pays an annual dividend of 80.00, which amounts to a dividend yield of 3.35%.
| Dividend Per Share | 80.00 |
| Dividend Yield | 3.35% |
| Dividend Growth (YoY) | 5.41% |
| Years of Dividend Growth | 10 |
| Payout Ratio | 46.68% |
| Buyback Yield | 0.00% |
| Shareholder Yield | 3.16% |
| Earnings Yield | 7.06% |
| FCF Yield | 12.16% |
Stock Splits
The last stock split was on March 27, 2014. It was a forward split with a ratio of 5.
| Last Split Date | Mar 27, 2014 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
Astellas Pharma has an Altman Z-Score of 2.48 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.48 |
| Piotroski F-Score | 7 |